Chemicals Group Lonza Sells Singapore Unit to Roche

Aug. 31, 2009
Purchase price of the cell culture biologic manufacturing facility was $290 million

Swiss chemicals group Lonza said August 31 that it has signed a deal to sell a manufacturing facility in Singapore to a Roche-owned subsidiary for up to $360 million.

The purchase price of the cell culture biologic manufacturing facility was $290 million while an additional $70 million would be paid up if certain milestones were met, Lonza said.

Swiss pharmaceutical giant Roche said the facility will be merged with an existing facility run by its subsidiary Genentech Singapore.

Some 230 Lonza employees at the site would also join Genentech Singapore.

Copyright Agence France-Presse, 2009

Popular Sponsored Recommendations

Empowering the Modern Workforce: The Power of Connected Worker Technologies

March 1, 2024
Explore real-world strategies to boost worker safety, collaboration, training, and productivity in manufacturing. Emphasizing Industry 4.0, we'll discuss digitalization and automation...

3 Best Practices to Create a Product-Centric Competitive Advantage with PRO.FILE PLM

Jan. 25, 2024
Gain insight on best practices and strategies you need to accelerate engineering change management and reduce time to market. Register now for your opportunity to accelerate your...

Transformative Capabilities for XaaS Models in Manufacturing

Feb. 14, 2024
The manufacturing sector is undergoing a pivotal shift toward "servitization," or enhancing product offerings with services and embracing a subscription model. This transition...

Shifting Your Business from Products to Service-Based Business Models: Generating Predictable Revenues

Oct. 27, 2023
Executive summary on a recent IndustryWeek-hosted webinar sponsored by SAP

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!